FeesSafety
Pluang+

Compare Merck & Co., Inc. (MRK) vs Microsoft (MSFT) Price & Performance

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Microsoft — how do they compare? Merck & Co., Inc. trades at $133.72 (market cap $329.65B), while Microsoft trades at $484.52 (market cap $3.60T). The key difference: Microsoft is far larger — about 10.9× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.63%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Microsoft for 146 Days on average.

MRKMSFT
Market Cap
$329.65B$3.60T
Volume
15,606,39047,123,194
Sector
HealthTechnology
52-Week High
$156.43$555.80
52-Week Low
$96.89$352.83
Typical Hold Time
98 Days146 Days
Enterprise Value
$373.78B$3.59T
Dividend Yield
2.63%0.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $133.72, up 0.74% on the day, with a bearish technical signal but strong earnings beats in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a net margin of 28.07%. Recent acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while cash flow from operations remains robust at $16.47B in 2025.

The outlook is mixed: analyst consensus is bullish with a $159.45 price target, but high P/E of 135.07 and bearish technicals pose risks. Key opportunities include pipeline expansion and dividend payments, while risks involve valuation concerns and competitive pressures in the pharma sector.

Microsoft

Microsoft (MSFT) trades at $484.52, down 2.77% today amid a broader tech pullback, but maintains strong fundamentals with a P/E of 25.3 and robust profitability margins. Recent earnings have consistently beaten estimates, and the company's revenue growth trajectory remains solid, supported by AI and cloud investments. Technical indicators show a bearish short-term trend, with support near $461, while analyst consensus remains overwhelmingly positive with a $617.36 price target.

The outlook for MSFT is favorable long-term due to its leadership in AI and cloud computing, though near-term risks include high capital expenditure concerns and competitive pressures. Investors should weigh the stock's current valuation against its growth potential and consistent earnings performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK →

About Microsoft

Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.

Read more on MSFT →